Ozempic, Wegovy, Mounjaro and your eyes: what GLP-1 patients should know about vision

First, do not stop your medication over a headline

These drugs do real good. They lower blood sugar, protect the heart and kidneys, and help people lose weight that was hurting their health. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society said the same thing the FDA did: do not stop a GLP-1 medication on your own because of this announcement. That decision belongs in a conversation with the doctor who prescribed it.

What the news does mean is that your eyes are now officially part of the picture. That is the part worth acting on.

Which medications this covers

The warning applies to the whole class, not one brand. That includes semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound), which acts on both the GIP and GLP-1 receptors. Most of the research so far has been on semaglutide, and the data on the others is thinner, but the FDA applied the warning across the board.

The condition behind the warning: NAION

NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms, blood flow to the front of the optic nerve drops, and the nerve is injured. People often describe it as an eye stroke. It usually shows up as sudden, painless vision loss in one eye, frequently noticed on waking.

It is rare. In adults over 50, NAION affects somewhere between 2 and 10 people out of every 100,000 each year. When the FDA pooled 126 clinical trials covering more than 134,000 patients, it found 15 probable cases: 10 in people taking a GLP-1 medication and 5 in people who were not. That works out to about 6.4 cases per 100,000 patient years on the medication versus 3.8 without it.

So the honest summary is this. The risk appears to be higher on these medications, it is still very small, and nobody has proven the drug is the cause. The FDA called it a potential increased risk. There is also no treatment that reverses NAION once it happens, which is exactly why recognizing it early and protecting the other eye matters.

The bigger issue for people with diabetes: the retina

NAION gets the headlines, but for patients with diabetes there is a more common concern. When blood sugar comes down quickly after being high for a long time, diabetic retinopathy can temporarily get worse before it gets better. Doctors have known about this for decades, long before these drugs existed, and it has been seen with insulin too.

In one large semaglutide trial, retinopathy complications occurred in 3 percent of patients on the drug compared with 1.8 percent on placebo. Almost all of them already had retinopathy when they started and had a large, fast drop in their A1c. The evidence since then has been mixed, and the Academy notes that studies do not consistently show these medications worsen retinopathy. A dedicated trial is still running.

The practical lesson does not depend on how that debate ends. If you have diabetes, the state of your retina on the day you start matters. Someone with healthy retinas is in a very different position from someone with untreated retinopathy who is about to drop their A1c three points in four months. You cannot know which one you are without a dilated exam.

What about macular degeneration?

A 2025 Canadian study of older adults with diabetes found that those on GLP-1 medications were about twice as likely to develop wet macular degeneration. That sounds alarming until you see the actual numbers: 0.2 percent versus 0.1 percent over roughly two and a half years. It was an observational study, which means it shows a pattern and cannot prove a cause. It is worth knowing about, and worth mentioning to your eye doctor if macular degeneration runs in your family.

Blurry vision in the first few months

This is the complaint we hear most, and it is usually the least dangerous. Blood sugar affects the lens inside your eye. When your sugar changes quickly, the lens changes shape slightly and your focus shifts. Glasses that were fine last month suddenly seem wrong.

It typically settles once your sugar stabilizes. Two pieces of advice. Do not rush out for a new glasses prescription while your numbers are still moving, because it will likely change again. And do not assume every blur is this harmless kind. Gradual blur in both eyes that comes and goes is one thing. Sudden loss of vision in one eye is something else entirely.

Symptoms that mean call right away

Contact an eye doctor the same day, or go to an emergency room, if you notice any of these:

• Sudden, painless loss of vision in one eye, especially when you wake up
• A dark area, blind spot or missing section in your field of view
• Colors that suddenly look faded or washed out in one eye
• A new shower of floaters, flashes of light, or a curtain across your vision
• Straight lines that suddenly look bent or wavy

Why we recommend an eye exam as part of your treatment

We want to be accurate about what the experts say. The Academy does not recommend an eye exam solely to screen for NAION before starting a GLP-1, because no test can predict who will get it. That is true, and we are not going to tell you otherwise.

But that is a narrow statement about one rare condition. It is not a statement that your eyes do not need attention. If you have diabetes, a regular dilated eye exam, typically every year, is already the standard of care, and far too many patients skip it. Starting a medication that will change your blood sugar quickly is the best reason there is to stop skipping it.

A comprehensive dilated exam gives you a baseline. We document your optic nerves, check your retinas for any retinopathy, image the macula, and record your vision. If something changes six months into treatment, we are comparing against a real record of your eyes instead of guessing. If we find retinopathy that nobody knew about, your prescribing doctor can factor that into how fast they bring your sugar down. And if you have already had NAION in one eye, or you have risk factors like sleep apnea, high blood pressure or smoking, that is a conversation to have before you start, not after.

Our recommendation is simple. Get a baseline dilated exam when you start a GLP-1 medication, or now if you are already on one and have not had one. Keep up with yearly exams, more often if we find something to watch. Tell us what you are taking and when your dose changes.

Staying on top of it

These medications are helping millions of people, and for most of them the eyes will never be an issue. The patients who do run into trouble are overwhelmingly the ones whose eyes nobody was watching. That is a problem an exam solves.

At Rand Eye Institute, your exam, retinal imaging and any treatment you might need all happen in one building in Deerfield Beach. If you are on a GLP-1 medication or about to start one, call us and tell the scheduler. We will get your baseline on file.